| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.9 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |